Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 01 Sep 2011 Results published in the Diabetes, Obesity and Metabolism.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2009 Primary endpoint 'Insulin levels' has been met according to results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD)..